Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation

IF 4.5 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-07-14 DOI:10.1016/j.lungcan.2024.107893

Lorenzo Belluomini , Ursula Cesta Incani , Annafrancesca Smimmo , Alice Avancini , Marco Sposito , Jessica Insolda , Ilaria Mariangela Scaglione , Federica Gattazzo , Simone Caligola , Annalisa Adamo , Fabiana Conciatori , Chiara Bazzichetto , Stefano Ugel , Diana Giannarelli , Sara Pilotto , Michele Milella

{"title":"Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation","authors":"Lorenzo Belluomini , Ursula Cesta Incani , Annafrancesca Smimmo , Alice Avancini , Marco Sposito , Jessica Insolda , Ilaria Mariangela Scaglione , Federica Gattazzo , Simone Caligola , Annalisa Adamo , Fabiana Conciatori , Chiara Bazzichetto , Stefano Ugel , Diana Giannarelli , Sara Pilotto , Michele Milella","doi":"10.1016/j.lungcan.2024.107893","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>High interleukin-8 (IL-8) levels have been linked to poor prognosis in lung cancer, but conclusive data are lacking.</p></div><div><h3>Materials and methods</h3><p>A comprehensive search was conducted on April 1st, 2023, from electronic databases, focusing on studies with IL-8 expression evaluations and the availability of hazard ratio (HR) and 95% confidence intervals (CI) for overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) or adequate data for their estimation. Then, we examined IL-8 and CXCR1 RNA-seq data from The Cancer Genome Atlas (TCGA) dataset, and we correlated these data with OS.</p></div><div><h3>Results</h3><p>Among 2655 produced records, 10 manuscripts involving both non-small cell lung cancer and small cell lung cancer, were included in the analysis. Two manuscripts and one study included two and three different cohorts, respectively, for a total of 14 cohorts of patients. Overall, 4 cohorts evaluated IL-8 levels in patients treated with chemotherapy, 3 cohorts immunotherapy, 2 cohorts surgical patients and 4 cohorts other treatments; 1 cohort was removed, as the type of treatments was lacking. The 12 cohorts included in the OS analysis revealed that patients with high IL-8 levels have a lower OS probability, as compared to patients with low IL-8 levels (HR=1.75, 95 % CI 1.36–2.26). No significant difference between patients with high and low IL-8 levels was observed in the 8 cohorts available for PFS analysis. Sensitivity analysis according to treatment revealed significant PFS and OS differences for patients treated with chemotherapy or immunotherapy. Analysis of RNA-seq data from TCGA, confirmed the correlation between high IL-8 and CXCR1 expression and worse OS in patients with resected lung cancer.</p></div><div><h3>Conclusion</h3><p>To the best of our knowledge, this study represents the first <em>meta</em>-analysis demonstrating a negative prognostic impact of high IL-8 level in lung cancer, particularly in patients treated with chemotherapy and/or immunotherapy.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107893"},"PeriodicalIF":4.5000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224004276/pdfft?md5=51ea460145370293504ec1e00a8a0097&pid=1-s2.0-S0169500224004276-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224004276","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

High interleukin-8 (IL-8) levels have been linked to poor prognosis in lung cancer, but conclusive data are lacking.

Materials and methods

A comprehensive search was conducted on April 1st, 2023, from electronic databases, focusing on studies with IL-8 expression evaluations and the availability of hazard ratio (HR) and 95% confidence intervals (CI) for overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) or adequate data for their estimation. Then, we examined IL-8 and CXCR1 RNA-seq data from The Cancer Genome Atlas (TCGA) dataset, and we correlated these data with OS.

Results

Among 2655 produced records, 10 manuscripts involving both non-small cell lung cancer and small cell lung cancer, were included in the analysis. Two manuscripts and one study included two and three different cohorts, respectively, for a total of 14 cohorts of patients. Overall, 4 cohorts evaluated IL-8 levels in patients treated with chemotherapy, 3 cohorts immunotherapy, 2 cohorts surgical patients and 4 cohorts other treatments; 1 cohort was removed, as the type of treatments was lacking. The 12 cohorts included in the OS analysis revealed that patients with high IL-8 levels have a lower OS probability, as compared to patients with low IL-8 levels (HR=1.75, 95 % CI 1.36–2.26). No significant difference between patients with high and low IL-8 levels was observed in the 8 cohorts available for PFS analysis. Sensitivity analysis according to treatment revealed significant PFS and OS differences for patients treated with chemotherapy or immunotherapy. Analysis of RNA-seq data from TCGA, confirmed the correlation between high IL-8 and CXCR1 expression and worse OS in patients with resected lung cancer.

Conclusion

To the best of our knowledge, this study represents the first meta-analysis demonstrating a negative prognostic impact of high IL-8 level in lung cancer, particularly in patients treated with chemotherapy and/or immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

白细胞介素-8水平对肺癌预后的影响：荟萃分析和生物信息学验证

背景：高白细胞介素-8（IL-8）水平与肺癌的不良预后有关，但目前尚缺乏确凿的数据：2023年4月1日，我们在电子数据库中进行了一次全面检索，重点是对IL-8表达进行评估，并提供总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）的危险比（HR）和95%置信区间（CI）或足够的数据用于估算的研究。然后，我们研究了癌症基因组图谱（TCGA）数据集中的IL-8和CXCR1 RNA-seq数据，并将这些数据与OS相关联：在2655条记录中，有10篇同时涉及非小细胞肺癌和小细胞肺癌的稿件被纳入分析。两篇稿件和一项研究分别包含了两个和三个不同的队列，共计 14 个队列的患者。总体而言，4个队列评估了化疗患者的IL-8水平，3个队列评估了免疫疗法患者的IL-8水平，2个队列评估了外科手术患者的IL-8水平，4个队列评估了其他疗法患者的IL-8水平。纳入 OS 分析的 12 个队列显示，与 IL-8 水平低的患者相比，IL-8 水平高的患者 OS 概率较低（HR=1.75，95 % CI 1.36-2.26）。在可进行PFS分析的8个队列中，未观察到IL-8水平高和低的患者之间存在明显差异。根据治疗方法进行的敏感性分析显示，接受化疗或免疫治疗的患者的 PFS 和 OS 有明显差异。来自TCGA的RNA-seq数据分析证实了IL-8和CXCR1高表达与切除肺癌患者较差的OS之间的相关性：据我们所知，该研究是首个证明高IL-8水平对肺癌预后有负面影响的荟萃分析，尤其是在接受化疗和/或免疫治疗的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.